Beacon Harbor Wealth Advisors Inc. Decreases Stock Position in Pfizer Inc. $PFE

Beacon Harbor Wealth Advisors Inc. lessened its stake in Pfizer Inc. (NYSE:PFE) by 26.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 190,860 shares of the biopharmaceutical company’s stock after selling 70,393 shares during the period. Beacon Harbor Wealth Advisors Inc.’s holdings in Pfizer were worth $4,626,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of PFE. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer in the first quarter worth approximately $27,000. Curio Wealth LLC raised its holdings in Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,098 shares during the last quarter. Bayforest Capital Ltd purchased a new stake in Pfizer during the 1st quarter valued at $28,000. Harbor Asset Planning Inc. bought a new stake in Pfizer in the 2nd quarter worth $29,000. Finally, WPG Advisers LLC bought a new stake in Pfizer in the 1st quarter worth $35,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Down 2.8%

PFE stock opened at $25.08 on Friday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69. The company has a market capitalization of $142.57 billion, a price-to-earnings ratio of 13.34, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. The business’s 50 day moving average price is $24.80 and its two-hundred day moving average price is $24.44. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on PFE shares. Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research note on Wednesday, August 6th. UBS Group restated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Scotiabank initiated coverage on Pfizer in a report on Thursday. They issued a “sector outperform” rating and a $30.00 price objective for the company. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $28.28.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.